Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇵🇱PL · Life Sciences#3810K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
3K to 9K🎙 Daily cadence·342 episodes·Last published 2d ago - Monthly Reach
Unique listeners across all episodes (30 days)
10K to 30K🇵🇱100% - Active Followers
Loyal subscribers who consistently listen
4K to 12K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 13 epsHost
Recent guests
Recent episodes
How we got Ozempic
Jul 8, 2026
4m 36s
Unlicensed Medical Advice & The Legal Battle Over Character.AI
May 18, 2026
15m 25s
Sponsoring Cannabis Research
May 6, 2026
4m 47s
The New Era of Personal Consent Decrees
Apr 30, 2026
8m 04s
Why Private Membership Associations Fail FDA Scrutiny
Apr 16, 2026
7m 03s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/8/26 |  How we got Ozempic | Send us Fan Mail How a "Failed" 4-Minute Molecule Created a Trillion-Dollar Cultural Eclipse Imagine pitching a drug to a room of venture capitalists that is biologically perfect—except for one tiny flaw: the human body completely destroys it in four minutes flat. That is the exact garbage hand Danish pharma giant Novo Nordisk was dealt in the 1990s. Today, that exact same molecule is Ozempic and Wegovy, a global phenomenon reshaping culture, tech, Hollywood, and global economies. But how did... | 4m 36s | ||||||
| 5/18/26 | Unlicensed Medical Advice & The Legal Battle Over Character.AI✨ | artificial intelligencemedical advice+4 | Elizabeth Litten | Fox RothschildCharacter.AI | Pennsylvania | AI chatbotmedical license+5 | — | 15m 25s | |
| 5/6/26 | Sponsoring Cannabis Research✨ | cannabis researchlegalization+4 | — | cannabisSchedule I+1 | U.S. | cannabisresearch+5 | — | 4m 47s | |
| 4/30/26 | The New Era of Personal Consent Decrees✨ | personal consent decreesfederal enforcement+4 | — | Office of Data ReliabilityKLF Playbook+1 | — | consent decreefederal enforcement+4 | — | 8m 04s | |
| 4/16/26 | Why Private Membership Associations Fail FDA Scrutiny✨ | Private Membership AssociationFDA oversight+4 | — | FDALittle v. Q Lasers | — | Private Membership AssociationFDA+5 | — | 7m 03s | |
| 4/11/26 | The Hidden Reason Sites are Firing Recruiters✨ | clinical trialsrecruitment+3 | — | KLFstate licensing boards+2 | — | clinical trialrecruitment fees+5 | — | 7m 57s | |
| 4/10/26 | Don’t Let Your PI Walk Away With Your Study✨ | clinical trialslegal architecture+3 | — | — | — | clinical trial sitesproprietary data+3 | — | 1m 06s | |
| 4/9/26 | Safe or Just "Not Dirty"? The Regulatory Gamble of Compounded Drugs✨ | compounded drugsFDA approval+3 | — | Mounjaro | — | compounded drugsFDA approval+4 | — | 2m 24s | |
| 4/6/26 | "Basically Employees" Isn't a Legal Category (And the OIG Knows It)✨ | compliancelife sciences+4 | — | OIGlife sciences | — | compliance theatercontract sales forces+3 | — | 3m 51s | |
| 4/3/26 | The Hidden Legal Risks of AI Sponsor Protocols✨ | AI in clinical researchdata integrity+4 | — | — | — | AIclinical research+4 | — | 0m 45s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 4/2/26 | The $100M Mistake: Why AI-Generated Drugs May Not Be Patentable✨ | AI in drug discoverybiotech risks+4 | — | — | — | AI-generated drugspatentable+5 | — | 3m 26s | |
| 3/30/26 | Is AI replacing your Doctor?✨ | AI in healthcaremedical technology+3 | — | New York TimesNature Medicine | — | AIdoctor+7 | — | 12m 57s | |
| 3/28/26 | Why the OIG Just Revolutionized Pharma Marketing (And What It Costs You)✨ | pharmaceutical marketinghealthcare policy+3 | — | HHS Office of Inspector GeneralTrumpRx | — | OIGpharmaceutical marketing+3 | — | 0m 53s | |
| 3/27/26 | 6 Categories of "Bulk Data" That Could Land You in Federal Court.✨ | bulk datafederal court+4 | — | DOJ | China | bulk sensitive personal datafederal violation+4 | — | 0m 42s | |
| 3/26/26 | The Utah Experiment: The Dangerous New Frontier of AI Prescribing | Send us Fan Mail Is your state "sandbox" a playground or a legal minefield? In this episode, Darshan Kulkarni—pharmacist and attorney—dissects the quiet movement of states like Utah allowing AI to manage and renew prescriptions. While the innovation is exciting, the federal government is watching closely. We break down the three massive risks facing life science companies and healthcare providers today: Clinical Logic Failures: Why a state sandbox can't fix bad AI medicine.The Liability Void:... | 1m 39s | ||||||
| 3/23/26 | Is Your DTC Program a Kickback Trap? | Send us Fan Mail The OIG has officially shifted the goalposts for Direct-to-Consumer (DTC) and Direct-to-Patient (DTP) programs. For years, federal healthcare discounts were a "no-go zone," but a new dual-track strategy is emerging—if you know how to build the firewall. In this episode, Darshan Kulkarni breaks down the three core regulatory pillars required to bypass PBM middlemen without triggering federal anti-kickback statutes. We discuss the "one-year commitment" rule, the "seeding"... | 3m 28s | ||||||
| 3/20/26 | The Hidden Death Sentence for Trial Sites | Send us Fan Mail In this episode of KLF Deep Dive, Darshan Kulkarni uncovers the catastrophic risks clinical trial sites face when they fail to vet their staff against federal exclusion lists. We move beyond simple compliance to discuss the "off-the-books" penalties that can end a career or a company. If you’re in the life sciences, this is the legal shield you can't afford to ignore. Support the show www.kulkarnilawfirm.com | 0m 33s | ||||||
| 3/19/26 | FDA "Screams": The Real Reason Your Snack Is At Risk | Send us Fan Mail Undeclared allergens remain the #1 cause of food recalls in the U.S., yet many brands still treat labeling as a "marketing" task rather than a "legal" one. In this episode of KLF Deep Dive, Darshan Kulkarni breaks down the regulatory horror stories of major brands—from Nugo to Frito-Lay—and explains why the FDA doesn't care if your co-manufacturer messed up. If your name is on the bag, you own the risk. Learn how to transition from "marketing font arguments" to FSMA-compliant... | 9m 30s | ||||||
| 3/16/26 | 2 Laws More Dangerous Than HIPAA for Patient Engagement | Send us Fan Mail Think HIPAA is your biggest hurdle in pharma marketing? Think again. In this episode of KLF Deep Dive, Darshan Kulkarni reveals why focusing solely on HIPAA leaves a massive, unregulated gap in your compliance strategy. We break down the "layered system" of risk—from aggressive state privacy laws and medical privacy statutes to the DOJ’s massive 2025 Bulk Data Rule. Whether you’re running patient engagement campaigns or leveraging marketing automation, you’ll learn why ... | 2m 49s | ||||||
| 3/14/26 | "Invite-Only" Compliance Is Over: Is Your Cosmetic Company Ready? | Send us Fan Mail The "handshake" era of cosmetic compliance is officially over. Under new authorities in Sections 605, 610, and 704, the FDA has moved from simple observation to an aggressive "access and copy" mandate. In this episode, Darshan Kulkarni breaks down the "SAHCOD" threat and explains why your internal communications, medical assessments, and even cross-contamination logs are now fair game for federal investigators. If you handle raw materials or shared manufacturing equipme... | 3m 14s | ||||||
| 3/13/26 | Audit-Proof Your Site: The Training Gap Killing Your Contracts | Send us Fan Mail In clinical research, if it isn't documented, it never happened. Many site owners mistake a competent team for a compliant one—a mistake that leads to disastrous FDA inspections and lost sponsor contracts. In this KLF Deep Dive, Darshan Kulkarni reveals the specific training SOPs, log templates, and contract clauses required to protect your site. Learn how to bridge the gap between "doing the work" and "proving the work" so you can demonstrate a culture of readiness tha... | 0m 46s | ||||||
| 3/12/26 | 15 Years in Prison for Marketing Fraud | Send us Fan Mail Is your marketing team building a brand or a federal case? In this episode, we deconstruct the $1.2 billion collapse of Boom Care. What looked like a runaway success story in the wound care space was actually a systematic violation of the False Claims Act. We break down the three fatal mistakes that led to 15-year prison sentences for executives: prioritizing reimbursement over medical necessity, incentivizing volume over value, and treating compliance as an afterthough... | 2m 49s | ||||||
| 3/11/26 | Is your "Clinical Decision Support" tool actually an unregulated medical device? | Send us Fan Mail In January 2026, the FDA sharpened the line between helpful software and regulated medical devices. If your AI sits inside an EHR, providing "black box" recommendations that a clinician can’t independently verify in seconds, you aren't just drifting into a regulatory gray area, you’re likely standing outside the "safe zone." In this episode, we break down the high-stakes intersection of FDA transparency, OIG inducement analysis, and the reality of clinical workflows. In this ... | 3m 34s | ||||||
| 3/10/26 | The FDA’s New Political Enforcement Strategy | Send us Fan Mail In this episode, Darshan Kulkarni exposes a massive legal shift that is quietly dismantling the "Practice of Medicine" defense. We track the whiplash from the 2021 Ivermectin court victories to the DOJ’s aggressive 2025 memorandum targeting gender-affirming care. Is "Intended Use" being weaponized as a high-tech surveillance tool? If the government can criminalize the intent behind a legal hormone, what does that mean for every manufacturer and physician operating in the off-... | 4m 48s | ||||||
| 3/9/26 | Why Your "Physician-Only" Ads Aren't Safe from Regulators | Send us Fan Mail In this episode of the KLF Deep Dive, Darshan Kulkarni sits down with Phyllis Marcus, Vice President of the National Advertising Division (NAD) and former FTC veteran. They unpack the complex "grey area" where healthcare professional (HCP) communications bleed into the public consumer space. Phyllis reveals why labeling an ad "For Healthcare Professionals Only" may no longer protect a company from regulatory scrutiny and explains the NAD’s role as an independent adjudic... | 22m 57s | ||||||
Showing 25 of 346
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.